BioSpace News Archive

Origami Therapeutics http://origamitherapeutics.com , an early stage biotech company taking a precision medicine approach to find disease-modifying treatments for neurodegenerative diseases caused by protein folding, announced today it has been selected as one of the 60 “Cool Companies” for 2020 by Connect with San Diego Venture Group. Ori

Asymptomatic healthcare professionals who work in pediatric emergency department in a community with a low prevalence of COVID-19 and who undergo daily health screenings are not likely to be carriers of the virus, according to a new study from CHOC Children’s.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, the research partner of ThermoGenesis’ joint venture, ImmuneCyte, Inc.,

The U.S. Food and Drug Administration and the National Telecommunications and Information Administration (NTIA) are launching a 120-day pilot to help reduce the availability of unapproved opioids illegally offered for sale online.

AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a new competition that will support cutting-edge research that could significantly improve diagnostic testing and patient care.

Aquavit Pharmaceuticals, Inc. (Aquavit), a biotechnology company focused on the development of a first-of-its-kind microchannel drug delivery technology, is proud to announce its participation in the 2020 BIO International Convention which will take place for the first time in a fully digital format

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced top-line results from the Company’s Phase III trial, DESTINY PWS (C601), evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for patients with Prader-Willi Syndrome (PWS).

Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject to market and other conditions. All of the shares are being offered by Retrophin

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase-R (PKR) activator mitapivat for the treatment of patients with thalassemia.

Vireo Health International, Inc. (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-led, science-focused, multi-state cannabis company, today announced that the Company has elected to terminate its employment agreement with Bruce Linton as Executive Chairman, on an entirely without-cause basis, effective immediately.